BSC
DNTH icon

BOLTON SECURITIES CORPORATION’s Dianthus Therapeutics DNTH Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.23K Buy
14
+7
+100% +$727 ﹤0.01% 2150
2026
Q2 		$682 Buy
+7
New +$611 ﹤0.01% 2164

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's DNTH Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION increased its Dianthus Therapeutics (DNTH) stake by 100% in Q3 2026, buying an estimated $727 and bringing the position to 14 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2150.

BOLTON SECURITIES CORPORATION first reported a position in DNTH in Q2 2026 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • BOLTON SECURITIES CORPORATION held 14 shares of Dianthus Therapeutics worth $1.23K as of Q3 2026.
  • BOLTON SECURITIES CORPORATION bought 7 Dianthus Therapeutics shares in Q3 2026, an estimated $727.
  • Dianthus Therapeutics made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #2150 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Dianthus Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.